A congressional committee is asking Gilead Sciences (GILD) to clarify its pricing insurance policies for the Truvada HIV prevention tablet, the newest effort to stress the drug maker over a drugs that has stirred controversy because of its excessive price and federally funded analysis help.
In a letter despatched on Wednesday to the corporate, the Home Committee on Oversight and Reform requested for explanations for Truvada worth hikes over the previous decade, in addition to correspondence with federal businesses about donations to the U.S. authorities and patents associated to HIV prevention. The committee additionally needs knowledge on the fee to fabricate Truvada and a forthcoming follow-up tablet referred to as Descovy.
Authoritative biopharma protection and evaluation, interviews with business pioneers, coverage evaluation, and first appears to be like at leading edge laboratories and early stage analysis
Subscriber-only networking occasions and panel discussions throughout the nation
Month-to-month subscriber-only dwell chats with our reporters and specialists within the subject
Discounted tickets to business occasions and early-bird entry to business experiences